Key Takeaways:
Moderna's experimental norovirus vaccine mRNA-1403 missed the pre-specified statistical threshold for early success in a Phase 3 interim analysis, the company said Thursday.
"The study remains ongoing, and we are enrolling an additional cohort to evaluate the seasonal vaccine's efficacy during the coming winter season," Moderna said in its Q2 2026 earnings release.
Shares of Moderna (NASDAQ: MRNA) fell about 7 percent in morning trading. The miss extends a trial that has stretched across three enrollment seasons, an FDA clinical hold, and a case-accrual shortfall on two continents. The company did not disclose the observed efficacy point estimate, consistent with the blinded study design.
Missing the interim bar does not mean the vaccine was proven ineffective. The statistical threshold for early stopping is set higher than the bar for the final readout, because examining accumulating data multiple times inflates the risk of a false positive. The trial remains blinded and ongoing, with a definitive efficacy readout now unlikely before the 2027-2028 timeframe.
The Nova 301 trial dosed its first participant in September 2024, timed to the Northern Hemisphere norovirus season. After struggling to accrue cases in the Southern Hemisphere, the trial returned north for a second season. In February 2025, the FDA placed the study on clinical hold following a single report of Guillain-Barré syndrome, a rare neurological condition; the hold was lifted about May 2025. A single case among roughly 25,000 participants does not establish a causal link.
mRNA-1403 is a trivalent vaccine encoding the major capsid protein of three norovirus genotypes — GII.4, GI.3, and GII.3 — delivered in lipid nanoparticles. Phase 1/2 data confirmed strong HBGA-blocking antibody responses against all three targets. The science appears sound; the constraint is epidemiology. Norovirus circulates in geographically uneven, year-to-year variable waves driven by outbreak clusters, making case accrual unpredictable.
No approved norovirus vaccine exists anywhere in the world. The disease causes about 21 million cases, 109,000 hospitalizations, and 900 deaths annually in the US, mostly among adults 65 and older, with an economic cost exceeding $5.5 billion. Globally, norovirus causes an estimated 200,000 deaths per year. HilleVax's HIL-214 failed a Phase 2b trial in infants in July 2024 with 5 percent efficacy, though its adult program showed 61.8 percent effectiveness in a separate study.
The norovirus setback complicates Moderna's push to diversify beyond respiratory vaccines. The company reported a Q2 net loss of $782 million, or $1.97 per share, on revenue of $145 million, with cash and investments of $6.9 billion at June 30. Investors will watch Aug. 5, when the FDA decides on mFLUSIVA, Moderna's mRNA flu vaccine, which an advisory panel recommended unanimously in June. Approval would give Moderna its first vaccine against a routine, annually recurring disease.
This article is for informational purposes only and does not constitute investment advice.
